Log in to save to my catalogue

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lun...

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lun...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_016854fb9481433287e7d8721af2694e

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

About this item

Full title

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

Publisher

United States: Elsevier B.V

Journal title

Molecular oncology, 2016-10, Vol.10 (8), p.1317-1329

Language

English

Formats

Publication information

Publisher

United States: Elsevier B.V

More information

Scope and Contents

Contents

Mesothelin overexpression in lung adenocarcinomas correlates with the presence of activating KRAS mutations and poor prognosis. Hence SS1P, a mesothelin-targeted immunotoxin, could offer valuable treatment options for these patients, but its use in solid tumor therapy is hampered by high immunogenicity and non-specific toxicity. To overcome both ob...

Alternative Titles

Full title

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_016854fb9481433287e7d8721af2694e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_016854fb9481433287e7d8721af2694e

Other Identifiers

ISSN

1574-7891

E-ISSN

1878-0261

DOI

10.1016/j.molonc.2016.07.003

How to access this item